ir.syndax.com
Investors – SyndaxThe Investor Relations website contains information about Syndax Pharmaceuticals, Inc. business for stockholders, potential investors, and financial analysts.
http://ir.syndax.com/
The Investor Relations website contains information about Syndax Pharmaceuticals, Inc. business for stockholders, potential investors, and financial analysts.
http://ir.syndax.com/
TODAY'S RATING
>1,000,000
Date Range
HIGHEST TRAFFIC ON
Sunday
LOAD TIME
2.3 seconds
PAGES IN
THIS WEBSITE
20
SSL
EXTERNAL LINKS
15
SITE IP
206.200.251.19
LOAD TIME
2.266 sec
SCORE
6.2
Investors – Syndax | ir.syndax.com Reviews
https://ir.syndax.com
The Investor Relations website contains information about Syndax Pharmaceuticals, Inc. business for stockholders, potential investors, and financial analysts.
ir.syndax.com
Investment Calculator – Syndax
http://ir.syndax.com/calculator.cfm
Annual Reports and Proxies. Calculate Current Value and Shares Since: March 3, 2016. There are no adjustments for your investment. 2017 Syndax Terms of Use.
Corporate Governance – Syndax
http://ir.syndax.com/corporate-governance.cfm
Annual Reports and Proxies. File is in Briefcase. File is in Briefcase. Nominating and Corporate Governance Committee Charter. File is in Briefcase. File is in Briefcase. Code of Business Conduct and Ethics. File is in Briefcase. Add file to Briefcase. 2017 Syndax Terms of Use.
SEC Filings – Syndax
http://ir.syndax.com/sec.cfm
Annual Reports and Proxies. All (excl. Section 16). File is in Briefcase. Shea, richard p. File is in Briefcase. Amended statement of beneficial ownership. File is in Briefcase. Statement of beneficial ownership. File is in Briefcase. Amended statement of beneficial ownership. File is in Briefcase. File is in Briefcase. File is in Briefcase. File is in Briefcase. Metzger, michael a. File is in Briefcase. Meyers, michael l. File is in Briefcase. 10 results per page. 25 results per page. 50 results per page.
Financial Information – Syndax
http://ir.syndax.com/financials.cfm
Annual Reports and Proxies. Syndax Fourth Quarter 2016 Conference Call. Syndax Pharmaceuticals Reports Fourth Quarter and Year-end 2016 Financial Results and Provides Clinical and Business Update. File is in Briefcase. File is in Briefcase. Add PDF file to Briefcase. 2017 Syndax Terms of Use.
Analyst Coverage – Syndax
http://ir.syndax.com/analysts.cfm
Annual Reports and Proxies. Syndax Pharmaceuticals, Inc. is covered by the following analysts. Robert C. Hazlett. Joel Beatty, MD. Michael G. King, Jr. 2017 Syndax Terms of Use.
TOTAL PAGES IN THIS WEBSITE
20
Entinostat - Syndax
http://www.syndax.com/dev-entinostat.aspx
A Novel Oncology Drug Candidate. Syndax is developing entinostat as a combination therapy in multiple cancer indications, with our initial focus on tumors that have shown sensitivity to immunotherapy, including lung cancer, melanoma, ovarian cancer and triple-negative breast cancer. Entinostat is an oral, small molecule histone deacetylase, or HDAC, inhibitor that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing the body’s immune response to tumors.
Home - Syndax
http://www.syndax.com/index.aspx
At Syndax, we are determined to realize a future in which people. With cancer live longer and better than ever before. Search Questions. Find Answers. What types of cancer is Syndax addressing? What clinical trials is Syndax currently conducting? Who is on the leadership team at Syndax? Where can I see your product pipeline? How can my organization collaborate with Syndax? Syndax Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update. 2016 Syndax Terms of Use.
Clinical Trials - Syndax
http://www.syndax.com/dev-entinostat-bc.aspx
Exploring New Treatment Options for Cancer Patients. Syndax is developing entinostat as a combination therapy in multiple cancer indications with an initial focus on tumors that have shown sensitivity to immunotherapy. Entinostat is an oral small molecule histone deacetylase, or HDAC inhibitor that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing the body’s immune response to tumors. Entinostat as an Immunotherapy. We are working in collaboration with Merck and C...
Clinical Trials - Syndax
http://www.syndax.com/dev-entinostat-lc.aspx
Exploring New Treatment Options for Cancer Patients. Syndax is developing entinostat as a combination therapy in multiple cancer indications with an initial focus on tumors that have shown sensitivity to immunotherapy. Entinostat is an oral small molecule histone deacetylase, or HDAC inhibitor that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing the body’s immune response to tumors. Entinostat as an Immunotherapy. We are working in collaboration with Merck and C...
Clinical Trials - Syndax
http://www.syndax.com/dev-clinical.aspx
Exploring New Treatment Options for Cancer Patients. Syndax is developing entinostat as a combination therapy in multiple cancer indications with an initial focus on tumors that have shown sensitivity to immunotherapy. Entinostat is an oral small molecule histone deacetylase, or HDAC inhibitor that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing the body’s immune response to tumors. Entinostat as an Immunotherapy. We are working in collaboration with Merck and C...
About Us - Syndax
http://www.syndax.com/about_invst.aspx
At Syndax, we are determined to realize a future in which people with cancer live longer and better than ever before. Syndax is currently focused on developing an innovative pipeline of combination therapies in multiple cancer indications. Syndax is headquartered in Waltham, Massachusetts. 2016 Syndax Terms of Use.
Careers - Syndax
http://www.syndax.com/careers.aspx
Join the Syndax Team. Syndax offers a competitive salary and benefits package. Qualified candidates should submit their resume and cover letter with a statement of interest, availability, and experience in Word or PDF format to [email protected]. Syndax is an Equal Opportunity Employer. Oversee the operations of the accounting department, including optimizing the departmental organizational structure and processes to achieve department’s goals and objectives. Manage the accounting team. Experience with S...
Leadership - Syndax
http://www.syndax.com/about_mgmt.aspx
Briggs W. Morrison, M.D. Chief Executive Officer and Director. Michael A. Metzger President and Chief Operating Officer. Michael L. Meyers, M.D., Ph.D. Senior Vice President, Chief Medical Officer. Allan L. Shaw Chief Financial Officer, Treasurer and Secretary. Peter Ordentlich, Ph.D. Chief Technology Officer and Founder. 2016 Syndax Terms of Use.
Pipeline - Syndax
http://www.syndax.com/development.aspx
Syndax is a clinical stage biopharmaceutical company developing an innovative pipeline of combination therapies in multiple cancer indications. Entinostat is our oral, small molecule drug candidate that has direct effects on both cancer cells and immune regulatory cells, potentially enhancing the body’s immune response to tumors. The favorable safety profile of entinostat has been demonstrated in clinical trials in more than 900 cancer patients. 2016 Syndax Terms of Use.
Board of Directors - Syndax
http://www.syndax.com/about_board.aspx
Dennis G. Podlesak Chairman of the Board of Directors. Mr Podlesak received a B.A. and an M.B.A. from Pepperdine University, and has completed postgraduate studies at the Wharton School, University of Pennsylvania. Briggs W. Morrison, M.D. Chief Executive Officer and Director. Fabrice Egros, Ph.D. Director. Luke Evnin, Ph.D. Director. Kim P Kamdar, Ph.D. Director. Ivor Royston, M.D. Director. Richard P. Shea Director. George W. Sledge Jr., M.D. Director. 2016 Syndax Terms of Use.
TOTAL LINKS TO THIS WEBSITE
15
SWUIR Home
Welcome to SWU Institutional Repository. This is a service that collects, preserves, and distributes digital material. Select a community to browse its collections. Behavioral Science Research Institute. Center for Science Education. Educational and Psychological Test Bureau. Faculty of Agricultural Product Innovation And Technology. Faculty of Environmental Culture and Ecotourism. Faculty of Fine Arts. Faculty of Health Science. Faculty of Physical Education. Faculty of Social Science.
首页－ 西南政法大学机构知识库－ SWUPL Institutional Repository
JavaScript is disabled for your browser. Some features of this site may not work without it. DSpace is a digital service that collects, preserves, and distributes digital material. Repositories are important tools for preserving an organization's legacy; they facilitate digital preservation and scholarly communication. 随着国民经济的快速发展,中小型企业得到了快速发展,但是在社会竞争如此激烈的条件下,部分中小型企业由于战略管理缺失不仅不能快速发展,同时还面临着破产的可能。 本文主要探讨的是中小企业战略管理缺失与应对策略,在具体的分析过程中首先论述了中小企业战略管理现状,其次分析了中小企业战略管理缺失的原因,最后重点论述了加强中小企业战略管理缺失的应对策略。 2000 - 2016 (10).
Iramasuka Tours & Travel
Deprecated: Function set magic quotes runtime() is deprecated in /home/adjie/public html/iramasuka/textpattern/lib/txplib db.php on line 14. Iramasuka Tours and Travel. It is a great pleasure for us to provide you our reliable Sulawesi tour programs which more rich of wonderful unique cultures and natural beauties. And wonderful seatrek of TOGIAN. Should you require more information about our products, iramasuka will be your best choice. Round The South Sulawesi. Round The South East Sulawesi.
SYCAMORENET.COM
Synageva :: Investor Relations
Effective June 23, 2015 Synageva BioPharma Corp. is now part of Alexion Pharmaceuticals, Inc. You will be redirected in 10 seconds. Our Mission / Commitment. What is a Rare Disease? Section 16 Filings (3,4,5). Synageva BioPharma Corp. (NASDAQ: GEVA). Synageva is a biopharmaceutical company dedicated to discovering, developing and delivering medicines for patients with rare diseases and high unmet medical needs. We are passionate about our commitment to improving the lives of patients for generations ...
Investors – Syndax
Annual Reports and Proxies. Syndax Pharmaceuticals, Inc. is a late-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Through our pipeline agents, entinostat, a late stage, class 1 specific HDAC inhibitor and SNDX-6352, a phase 1 anti-CSF-1R monoclonal antibody, we are determined to realize a future in which people with cancer live longer and better than ever before. Syndax corporate headquarters are in Waltham, MA. Day High: 7.40.
Investor Relations | SYNNEX Corporation
Skip to main navigation. Technology Solutions Executive Team. New Age Electronics (U.S.). SYNNEX Completes Acquisition of Westcon-Comstor North America and Latin America Businesses. Annual Reports and Proxies. Mar 29, 2018. SYNNEX Corporation Reports First Quarter Fiscal 2018 Results. Mar 20, 2018. SYNNEX Corporation Launches Exclusive IT Reseller Community Focused on Technology Convergence. Sign up for email alerts. Mar 29, 2018 5:00 PM EDT. Q1 2018 SYNNEX Corporation Earnings Conference Call.
Synta Pharmaceuticals Corp : Investors : Investor Overview
Trials by Tumor Type. Synta Pharmaceuticals is an innovative, agile biopharmaceutical company focused on research, development and commercialization of novel oncology medicines that have the potential to change the lives of cancer patients. . 160;- 0.01. Aug 07, 2015 4:00 pm ET. Data provided by Nasdaq. Minimum 15 minutes delayed. Synta Reports Second Quarter 2015 Financial Results. Aug 06, 2015. Synta to Host Conference Call and Webcast of Second Quarter 2015 Financial Results on August 6, 2015.
Investor Center | Synthesis Energy Systems, Inc.
Skip to main navigation. How Syngas is Used. Why Syngas is Important. Global Need and Resources. The Future of Gasification. The Real Cost of Energy. SGT: How It Works. How Syngas is Used. Why Syngas is Important. Global Need and Resources. The Future of Gasification. The Real Cost of Energy. SGT: How It Works. DRI for Steel Production. Clean Economic. Sustainable. Growth With Blue Skies. Synthesis Energy Systems, Inc. 30th Annual ROTH Conference 2018 Presentation. Mar 26, 2018. Mar 12, 2018. Mar 5, 2018.
Investor Relations :: Synthetic Biologics, Inc. (SYN)
Jan 5, 2017. Synthetic Biologics' SYN-004 (ribaxamase) Achieves Primary Endpoint in Phase 2b Trial for C. difficile Infection (CDI). Sep 30, 2016. Sign Up for Email Alerts Sign Up Today. Our experienced management team holds an extensive clinical and commercial track record. View Board of Directors. Synthetic Biologics, Inc. Corporate Stock Transfer, Inc. 3200 Cherry Creek Drive South. Denver, CO 80209.
沈阳师范大学机构知识库: Home
CALIS Institutional Repository (CALIS IR) is the academic research infrastructure of school. It's a central, open-access repository of research by members of the Peking University. Research Field : 古生物学、地层学，专长于中生代植物及早期被子植物研究。 Research Field : 从事现、当代文学和前沿文化、文学研究。 Research Field : 两栖爬行动物资源和保护生物学研究工作. New in CALIS IR. Institutional Repository Project Group, Powered by DSpace Feedback. Number of Online Users: 212 Total of Site Visit: 3297032.
SOCIAL ENGAGEMENT